Expand JSPR Menu
JSPR MENU

JSPR Stock Posts


Unusual Option Volume

JSPR Jasper Therapeutics - Class A7.14-10.57 (-59.7%)

Jasper Therapeutics - Class A trades 2,214 contracts. The company has the following event: Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on Jan 8, 2025. News: Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria
Unusual Option Volume

JSPR Jasper Therapeutics - Class A18.50-2.37 (-11.4%)

Jasper Therapeutics - Class A trades 2,372 contracts. The company has the following event: Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on Jan 8, 2025.
Unusual Option Volume

JSPR Jasper Therapeutics - Class A20.47+1.20 (+6.2%)

Jasper Therapeutics - Class A trades 3,944 contracts. The company has the following event: Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on Jan 8, 2025. News: Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025
Unusual Option Volume

JSPR Jasper Therapeutics - Class A21.19+0.10 (+0.5%)

Jasper Therapeutics - Class A trades 2,361 contracts.
Unusual Option Volume

JSPR Jasper Therapeutics - Class A22.36+0.24 (+1.1%)

Jasper Therapeutics - Class A trades 2,430 contracts.
Unusual Option Volume

JSPR Jasper Therapeutics - Class A2.58+0.93 (+56.4%)

Jasper Therapeutics - Class A trades 2,863 contracts. The company has the following event: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR between Feb 15, 2023 and Feb 19, 2023. News: Jasper Therapeutics Announces New Positive Briquilimab Data to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR